Board of Directors
Dr. Joseph SinkuleFounder, Chief Executive Officer (CEO), Director and Chairman of the Board
Dr. Sinkule is the company’s Chief Executive Officer (CEO), Founder, and the Chairman of the Board of Directors. He has over 40 years of drug, biologic, and medical device R&D and commercialization experience. This serial entrepreneur is the founder and driving force behind the Company, its growing product portfolio, and its financing strategies. He has personally managed over 8 drug and biotech products successfully through FDA approval to market, 5 medical devices and 8 in vitro diagnostics. He has hired and managed both small and large teams of experienced people in pharma and biotech organizations, and managed contract research organizations (“CROs”) and contract development and manufacturing companies (“CDMOs”), working for large and small clients. After serving in academics and then in industry, Dr. Sinkule has evolved into a successful businessman and entrepreneur. He serves on the Board of two companies, and routinely consults for venture capitalist firms, investment banks, as well as both large and early-stage pharmaceutical and biotech companies.
Dr. Shalom HirshmanMedical Advisor and Director
Dr. Shalom Hirschman, M.D. is a preeminent research physician, a clinical medical expert, and entrepreneur in infectious diseases, oncology, and cancer supportive care. He is a key consulting advisor to the Company. As a young man, he served as an intern and resident in medicine at the Massachusetts General Hospital and Harvard Medical School, and then went on to a career in molecular biology and virology research at the National Institute of Health (NIH). During his career in medical research, he interacted closely with several Nobel Prize winners including Drs. Berson and Yalow (Nobel Prize for development of radioimmunoassays). He was recruited to The Mount Sinai School of Medicine and The Mount Sinai Hospital in New York City as Head of the Department of Infectious Diseases, and eventually he also became Vice-Chairman and Chairman of the Department of Medicine at Mount Sinai, where he remained for three decades. He still is asked to consult on difficult diagnostic dilemmas like the recent COVID-19 pandemic.
Dr. Samuel Zentman Independent Director
Dr. Zentman graduated from Wayne State University and the University of Michigan and holds a Ph.D. doctorate in Complex Analysis. He was a Mathematics professor at several divisions of the University of Detroit. And worked as a systems analyst, manager of Engineering Computer Center, and director of the Corporate Computer Center of American Motors Corporation. Dr. Zentman was the CFO and then CEO of Manhattan Textile Corporation, a privately held export firm in New York city. He was a Board member of several Tech and Medical start-ups including: Neuromedical Systems Inc., Amplification Technologies, Inc., Power Safe Technology Corp, and Hinson Hale Medical Technologies Inc. Sam is currently a Board member of Acorn Energy where he has serv3ed for over the past 15 years, and is the Chairman of the Audit Committee, and member of the Nominating Committee and Compensation Committee. Sam has extensive experience in dealing with early stage medical and technology companies. He also serves as the Chairman of the Board of several national non-profits organizations devoted to the quality of education in the U.S. and abroad. We believe Dr. Zentman is qualified to serve on our Board because of his decades of expertise in business management, public and private company finance, his insight in medical technologies, and his global contacts and business relationships.
Mr. Jon McGarityIndependent Director
Mr. McGarity is the President & CEO of EthiX Associates, which he founded in February 1996 and is a consultancy business serving the business needs of the healthcare industry with a focus on pharmaceuticals and biotechnology. In addition, he has been the Chief Operating Officer of MiClimate, Inc. since 2022 which has developed the first body temperature regulation device resulting in a change in the way people manage individual temperature sensitivities. He co- founded NeuroEM Therapeutics, Inc., which is currently evaluating transcranial electromagnetic therapy (TEMT) for the treatment of cognitive functioning in Alzheimer’s disease patients, and served as the founding CEO & Board Chairman and most recently as its Chief Business Officer until 2023. In addition he currently is an Advisor to the Biodesign Institute at Arizona State University. He is an original and current member of the Arizona Biosciences Roadmap Committee which provides strategic direction to the biosciences industry in Arizona. His pharmaceutical experience includes senior management positions with GlaxoSmithKline, Bristol Myers Squibb and Novartis (Sandoz Pharmaceuticals). Mr. McGarity has launched over 40 products as well as completing numerous business development deals involving product acquisitions, licensing, co-marketing and promotional arrangements. Mr. McGarity’s experience having held executive positions at “big pharma” companies, start-up operations, drug and biologics regulations, marketing and sales, and finance makes him qualified to serve as a director.